CLINICAL TRIALS PROFILE FOR BRINZOLAMIDE

All Clinical Trials for Brinzolamide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00121147 ↗	Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan	Completed	Alcon Research	N/A	2003-09-01	The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00121147 ↗	Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan	Completed	Hermann Eye Center	N/A	2003-09-01	The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00300079 ↗	Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension	Completed	University of California, San Diego	Phase 4	2006-09-01	This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1.0% compared to timolol 0.5% when added to a prostaglandin analogue (PGA) as adjunctive therapy over a 24 hour period in patients with glaucoma or ocular hypertension.
NCT00300079 ↗	Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 4	2006-09-01	This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1.0% compared to timolol 0.5% when added to a prostaglandin analogue (PGA) as adjunctive therapy over a 24 hour period in patients with glaucoma or ocular hypertension.
NCT00372827 ↗	Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 4	2004-02-01	The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
NCT00382226 ↗	IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy	Completed	Alcon Research	Phase 4	2006-09-01	Uncontrolled glaucoma patients being treated with a prostaglandin agent alone or in combination with adjunctive drugs in fixed or unfixed combinations, will be switched from their current therapy to travoprost/timolol fixed combination and either Azopt or placebo
NCT00440141 ↗	Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%	Completed	Allergan	Phase 4	2006-07-01	Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Clinical Trial Conditions for Brinzolamide

Condition Name

Condition Name for Brinzolamide
Intervention	Trials
Ocular Hypertension	34
Glaucoma	22
Open-Angle Glaucoma	14
Open Angle Glaucoma	4

Condition MeSH

Condition MeSH for Brinzolamide
Intervention	Trials
Glaucoma	42
Ocular Hypertension	37
Hypertension	28
Glaucoma, Open-Angle	26

Clinical Trial Locations for Brinzolamide

Trials by Country

Trials by Country for Brinzolamide
Location	Trials
United States	38
Greece	4
Germany	2
Brazil	2
Italy	2

Trials by US State

Trials by US State for Brinzolamide
Location	Trials
Texas	8
California	5
Georgia	3
Florida	3
Illinois	2

Clinical Trial Progress for Brinzolamide

Clinical Trial Phase

Clinical Trial Phase for Brinzolamide
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	15
Phase 2	6

Clinical Trial Status

Clinical Trial Status for Brinzolamide
Clinical Trial Phase	Trials
Completed	40
Terminated	6
Unknown status	3

Clinical Trial Sponsors for Brinzolamide

Sponsor Name

Sponsor Name for Brinzolamide
Sponsor	Trials
Alcon Research	33
University Hospital of Patras	2
Bausch & Lomb Incorporated	2

Sponsor Type

Sponsor Type for Brinzolamide
Sponsor	Trials
Industry	47
Other	15
NIH	1